Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy

Blood (2019) 134 (4): 353–362.

https://doi.org/10.1182/blood-2018-10-879643

Published: 2019

Includes: Supplemental data

Journal Articles

PET-Guided Treatment of Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase 3 Trial HD16 By the German Hodgkin Study Group

Michael Fuchs, Helen Goergen, Carsten Kobe, MD, Hans Eich, MD, Christian Baues, MD, Richard Greil, MD, Stephanie Sasse, MD, Josée M Zijlstra, MD, Andreas Lohri, MD, Andreas Rosenwald, Bastian von Tresckow, MD, Volker Diehl, MD, Georg Kuhnert, Markus Dietlein, MD, Peter Borchmann, MD, Andreas Engert, MD

Blood (2018) 132 (Supplement 1): 925.

https://doi.org/10.1182/blood-2018-99-114519

Published: 2018

Journal Articles

Rituximab Maintenance Treatment for a Maximum of 5 Years in Follicular Lymphoma: Final Results of the Randomized Phase III Trial SAKK 35/03

Christian Taverna, MD, Giovanni Martinelli, MD, Felicitas Hitz, MD, Walter Mingrone, MD, Thomas Pabst, MD PhD, Lidija Cevreska, MD PhD, Auro del Giglio, MD, Anna Vanazzi, MD, Daniele Laszlo, MD, Johann Raats, Daniel Rauch, Daniel Vorobiof, Andreas Lohri, MD, Emanuele Zucca, Celine Rueegsegger, Stephanie - Rondeau, Corinne Rusterholz, Michele Ghielmini

Blood (2018) 132 (Supplement 1): 1601.

https://doi.org/10.1182/blood-2018-99-116864

Published: 2018

Journal Articles

Prospective Long-Term Follow-up after First-Line Subcutaneous Cladribine Treatment in Patients with Hairy Cell Leukemia. a Study of the SAKK (Swiss Group for Clinical Cancer Research)

Rudolf A. Benz, MD, Kornelius Arn, MD, Martin Andres, Thomas Pabst, MD PhD, Urban Novak, Felicitas Hitz, MD, Reinhard Zenhäusern, Yves Chalandon, MD PhD, Ulrich Mey, MD, Sabine Blum, Daniel Rauch, Willy Nettekoven, Nathan Cantoni, MD, Mario Bargetzi, MD, Alix O'Meara, MD, Andreas Lohri, MD, Simona Berardi, PhD BSc, Qiyu Li, Georg Stussi, MD

Blood (2018) 132 (Supplement 1): 2875.

https://doi.org/10.1182/blood-2018-99-114301

Published: 2018

Journal Articles

Early Interim PET in Patients with Advanced-Stage Hodgkin's Lymphoma Treated within the Phase 3 GHSG HD18 Study

Blood (2017) 130 (Supplement 1): 737.

https://doi.org/10.1182/blood.V130.Suppl_1.737.737

Published: 2017

Journal Articles

Rituximab Plus Lenalidomide Versus Rituximab Monotherapy in Untreated Follicular Lymphoma Patients in Need of Therapy. First Analysis of Survival Endpoints of the Randomized Phase-2 Trial SAKK 35/10

Blood (2016) 128 (22): 1099.

https://doi.org/10.1182/blood.V128.22.1099.1099

Published: 2016

Journal Articles

Primary Progressive Disease in Hodgkin Lymphoma Patients: A Retrospective Analysis from the German Hodgkin Study Group

Stefanie Kreissl, MD, Helen Goergen, Bastian von Tresckow, MD, Karolin Behringer, MD, Jana Markova, MD, Andreas Lohri, MD, Julia Meissner, MD, Josée M Zijlstra, MD, Richard Greil, MD, Max S. Topp, MD, Martin Sökler, MD, Hartmut Döhner, MD, Volker Diehl, MD, Andreas Engert, MD, Peter Borchmann, MD

Blood (2015) 126 (23): 3941.

https://doi.org/10.1182/blood.V126.23.3941.3941

Published: 2015

Journal Articles

Rituximab Plus Lenalidomide Improves the Complete Remission Rate in Comparison with Rituximab Monotherapy in Untreated Follicular Lymphoma Patients in Need of Therapy. Primary Endpoint Analysis of the Randomized Phase-2 Trial SAKK 35/10

Blood (2014) 124 (21): 799.

https://doi.org/10.1182/blood.V124.21.799.799

Published: 2014

Journal Articles

Addition of Rituximab to BEACOPP escalated to Improve the Outcome of Early Interim PET Positive Advanced Stage Hodgkin Lymphoma Patients: Second Planned Interim Analysis of the HD18 Study.

Peter Borchmann, MD, Heinz Haverkamp, Andreas Lohri, MD, Stefanie Kreissl, MD, Richard Greil, MD, Jana Markova, MD, Michaela Feuring-Buske, MD, Julia Meissner, MD, Ulrich Dührsen, Nicole Engel, MD, Ulrich Keller, MD, Georg Maschmeyer, MD, Markus Dietlein, MD, Carsten Kobe, MD, Michael Fuchs, MD, Volker Diehl, MD, Andreas Engert, MD

Blood (2014) 124 (21): 500.

https://doi.org/10.1182/blood.V124.21.500.500

Published: 2014

Journal Articles

Rituximab Maintenance Treatment For a Maximum Of 5 Years In Follicular Lymphoma: Results Of The Randomized Phase III Trial SAKK 35/03

Christian J. Taverna, MD, Giovanni Martinelli, Felicitas Hitz, Walter Mingrone, Thomas Pabst, MD, Lidija Cevreska, Auro del Giglio, MD, Anna Vanazzi, Daniele Laszlo, Johann Raats, Daniel Rauch, Daniel A. Vorobiof, Andreas Lohri, MD, Emanuele Zucca, MD, Christine Biaggi Rudolf, Stephanie Rondeau, Corinne Rusterholz, Michele Ghielmini, MD

Blood (2013) 122 (21): 508.

https://doi.org/10.1182/blood.V122.21.508.508

Published: 2013

Journal Articles

Pegfilgrastim Use and Outcomes In Non-Hodgkin-Lymphoma Patients Receiving Chemotherapy In Clinical Practice: Combined Analysis Of The Austrian and Swiss E-Avare Studies

Wolfgang Willenbacher, MD, Ferdinand Haslbauer, MD, Peter Neumeister, MD, Anton Guttmann, MD, Roland Sperb, MD, Andreas Lohri, MD, Biagio Saldutto, lic. phil. I, Christine Jaeger, PhD, Carine Bast, MSc, Christoph Renner, MD

Blood (2013) 122 (21): 4855.

https://doi.org/10.1182/blood.V122.21.4855.4855

Published: 2013

Journal Articles

Relative Reduction of Residual Tumor Improves Outcome Prediction of PET After Effective Chemotherapy for Patients with Advanced Stage Hodgkin Lymphoma

Andreas Engert, MD, Carsten Kobe, MD, Heinz Haverkamp, Georg Kuhnert, Jana Markova, MD, Andreas Lohri, MD, Susanne Klutmann, MD, Holger Amthauer, MD, Volker Diehl, MD, Peter Borchmann, MD, Markus Dietlein, MD

Blood (2012) 120 (21): 3684.

https://doi.org/10.1182/blood.V120.21.3684.3684

Published: 2012

Journal Articles

Treatment of Stage I-II A Non-Bulky Hodgkin's Lymphoma (HL): An Individual Patient-Data Comparison of German Hodgkin Study Group (GHSG) HD10 and HD11 Combined-Modality Therapy (CMT) and NCIC Clinical Trials Group (NCIC CTG) HD.6 ABVD Alone

Blood (2012) 120 (21): 548.

https://doi.org/10.1182/blood.V120.21.548.548

Published: 2012

Journal Articles

Brentuximab Vedotin (SGN-35) in Patients with Relapsed/Refractory CD30-Positive Hematologic Malignancies without Prior High-Dose Chemotherapy and Stem Cell Transplantation.

Achim Rothe, MD, Stephanie Sasse, MD, Helen Goergen, Dennis A. Eichenauer, MD, Andreas Lohri, MD, Ulrich Jäger, Christopher Bangard, Andreas Engert, MD

Blood (2012) 120 (21): 2743.

https://doi.org/10.1182/blood.V120.21.2743.2743

Published: 2012

Journal Articles

Brentuximab vedotin for relapsed or refractory CD30 + hematologic malignancies: the German Hodgkin Study Group experience

Achim Rothe, Stephanie Sasse, Helen Goergen, Dennis A. Eichenauer, Andreas Lohri, Ulrich Jäger, Christopher Bangard, Boris Böll, Michael von Bergwelt Baildon, Sebastian Theurich, Peter Borchmann, Andreas Engert

Blood (2012) 120 (7): 1470–1472.

https://doi.org/10.1182/blood-2012-05-430918

Published: 2012

Journal Articles

Radioimmunotherapy (RIT) with 177 Lutetium-DOTA-Rituximab ( 177 LU-D- R): A Phase I/II - Study in 30 Patients with Relapsing Follicular, Mantle Cell and Other Indolent B-Cell Lymphomas

Andreas Lohri, MD, Flavio Forrer, MD, PhD, Benedetta Campana, Christoph Mamot, MD, Ralph Winterhalder, MD, Richard Herrmann, MD, Helmuth R Maecke, PhD, Jan Müller-Brand, MD

Blood (2008) 112 (11): 3055.

https://doi.org/10.1182/blood.V112.11.3055.3055

Published: 2008

Journal Articles

Dose-Intensified Combined Modality Treatment with 2 Cycles of BEACOPP Escalated Followed by 2 Cycles of ABVD and Involved Field Radiotherapy (IF-RT) Is Superior to 4 Cycles of ABVD and IFRT in Patients with Early Unfavourable Hodgkin Lymphoma (HL): An Analysis of the German Hodgkin Study Group (GHSG) HD14 Trial

Peter Borchmann, Andreas Engert, Annette Pluetschow, Michael Fuchs, Jana Markova, Andreas Lohri, Zdenek Kral, Richard Greil, Max Topp, Matthias Villalobos, Jose Zijlstra, MD, Martin Soekler, Harald Stein, Hans Theodor Eich, Rolf Peter Mueller, Volker Diehl

Blood (2008) 112 (11): 367.

https://doi.org/10.1182/blood.V112.11.367.367

Published: 2008

Journal Articles

Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma

Blood (2008) 112 (10): 3989–3994.

https://doi.org/10.1182/blood-2008-06-155820

Published: 2008

Journal Articles

High Dose Chemotherapy Using Beam without Autologous Rescue Followed by Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation for Refractory or Relapsing Lymphomas - A Comparison of Delayed Versus Immediate Transplantation.

Andreas S. Buser, MD, Martin Stern, MD, Christoph Bucher, MD, Caroline Arber, MD, Dominik Heim, MD, Joerg Halter, MD, Sandrine Meyer-Monard, MD, Georg Stussi, MD, Andreas Lohri, MD, Michele Ghielmini, MD, Andre Tichelli, MD, Jakob R. Passweg, MD, Alois Gratwohl, MD

Blood (2006) 108 (11): 5352.

https://doi.org/10.1182/blood.V108.11.5352.5352

Published: 2006

Journal Articles

Factors Prognostic for Response and Event Free Survival and Treatment Related Toxicity in 306 Patients with Follicular or Mantle Cell Lymphoma Randomized to Single Agent Rituximab Given at the Standard or at a Prolonged Schedule.

Michele Ghielmini, Kaspar Rufibach, Gilles Salles, Sergio Cogliatti, Leda Leoncini-Franscini, Claire Leger-Falandry, Martin Fey, Thomas Cerny, Giovanni Martinelli, Rolf Stahel, Andreas Lohri, Nicolas Ketterer, Martin Wernli

Blood (2004) 104 (11): 588.

https://doi.org/10.1182/blood.V104.11.588.588

Published: 2004

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy

PET-Guided Treatment of Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase 3 Trial HD16 By the German Hodgkin Study Group

Rituximab Maintenance Treatment for a Maximum of 5 Years in Follicular Lymphoma: Final Results of the Randomized Phase III Trial SAKK 35/03

Prospective Long-Term Follow-up after First-Line Subcutaneous Cladribine Treatment in Patients with Hairy Cell Leukemia. a Study of the SAKK (Swiss Group for Clinical Cancer Research)

Early Interim PET in Patients with Advanced-Stage Hodgkin's Lymphoma Treated within the Phase 3 GHSG HD18 Study

Rituximab Plus Lenalidomide Versus Rituximab Monotherapy in Untreated Follicular Lymphoma Patients in Need of Therapy. First Analysis of Survival Endpoints of the Randomized Phase-2 Trial SAKK 35/10

Primary Progressive Disease in Hodgkin Lymphoma Patients: A Retrospective Analysis from the German Hodgkin Study Group

Rituximab Plus Lenalidomide Improves the Complete Remission Rate in Comparison with Rituximab Monotherapy in Untreated Follicular Lymphoma Patients in Need of Therapy. Primary Endpoint Analysis of the Randomized Phase-2 Trial SAKK 35/10

Addition of Rituximab to BEACOPP escalated to Improve the Outcome of Early Interim PET Positive Advanced Stage Hodgkin Lymphoma Patients: Second Planned Interim Analysis of the HD18 Study.

Rituximab Maintenance Treatment For a Maximum Of 5 Years In Follicular Lymphoma: Results Of The Randomized Phase III Trial SAKK 35/03

Pegfilgrastim Use and Outcomes In Non-Hodgkin-Lymphoma Patients Receiving Chemotherapy In Clinical Practice: Combined Analysis Of The Austrian and Swiss E-Avare Studies

Relative Reduction of Residual Tumor Improves Outcome Prediction of PET After Effective Chemotherapy for Patients with Advanced Stage Hodgkin Lymphoma

Treatment of Stage I-II A Non-Bulky Hodgkin's Lymphoma (HL): An Individual Patient-Data Comparison of German Hodgkin Study Group (GHSG) HD10 and HD11 Combined-Modality Therapy (CMT) and NCIC Clinical Trials Group (NCIC CTG) HD.6 ABVD Alone

Brentuximab Vedotin (SGN-35) in Patients with Relapsed/Refractory CD30-Positive Hematologic Malignancies without Prior High-Dose Chemotherapy and Stem Cell Transplantation.

Brentuximab vedotin for relapsed or refractory CD30 + hematologic malignancies: the German Hodgkin Study Group experience

Radioimmunotherapy (RIT) with 177 Lutetium-DOTA-Rituximab ( 177 LU-D- R): A Phase I/II - Study in 30 Patients with Relapsing Follicular, Mantle Cell and Other Indolent B-Cell Lymphomas

Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma

High Dose Chemotherapy Using Beam without Autologous Rescue Followed by Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation for Refractory or Relapsing Lymphomas - A Comparison of Delayed Versus Immediate Transplantation.

Factors Prognostic for Response and Event Free Survival and Treatment Related Toxicity in 306 Patients with Follicular or Mantle Cell Lymphoma Randomized to Single Agent Rituximab Given at the Standard or at a Prolonged Schedule.

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only